ArticleChinese medicine2026
A systems herbal-to-molecule and transcriptomic strategy identifies emodin as an ESR1-targeting phytochemical driving thrombopoiesis.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Radiation-induced thrombocytopenia (RIT) is a major dose-limiting toxicity of radiotherapy, for which effective pharmacological interventions remain limited. Rhei Radix et Rhizoma (RR) is widely used in traditional medicine, yet its thrombopoietic activity and molecular basis have not been systematically defined. Here, we investigated the effects of RR on thrombopoiesis using an integrated herbal-to-molecule and transcriptomic strategy. RR extract and representative phytochemicals were screened for megakaryocyte (MK) differentiation in Meg-01, K562, and murine haematopoietic stem and progenitor cells (HSPCs), followed by validation in a mouse RIT model. Network pharmacology and transcriptomic analyses indicated that RR regulates thrombopoiesis through coordinated multi-pathway modulation. Emodin was identified as the principal bioactive constituent mediating these effects. Functionally, emodin promoted MK maturation and polyploidization in vitro, accelerated megakaryopoiesis and platelet recovery in irradiated mice. Integrated target prediction and experimental validation identified ESR1 as a direct functional target of emodin, supported by molecular docking, molecular dynamics simulations, CETSA, and DARTS assays. Mechanistically, emodin activated ESR1-dependent PI3K/AKT and JAK2/STAT3 signaling, leading to induction of lineage-specific transcription factors and enhanced platelet biogenesis. Collectively, these findings identify emodin as a key thrombopoietic constituent of RR and reveal an ESR1-centered regulatory axis in megakaryopoiesis, supporting its therapeutic potential for RIT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.